Patents by Inventor Federico Bernal

Federico Bernal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240002450
    Abstract: This disclosure features structurally-stabilized Ebola virus antiviral peptides. Also disclosed are methods of using such structurally-stabilized peptides in the treatment or prevention of an Ebola virus infection or Ebola virus disease.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 4, 2024
    Inventors: Federico Bernal, Amanda L. Whiting, Loren D. Walensky, Gregory H. Bird
  • Patent number: 10822374
    Abstract: Compositions and methods for increasing p53-dependent transcriptional activity in a cell.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: November 3, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Salk Institute for Biological Studies
    Inventors: Loren D. Walensky, Federico Bernal, Geoffrey Wahl, Mark Wade
  • Patent number: 10202431
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: February 12, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • Patent number: 9783586
    Abstract: The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphoma (ABC DLBCL) and autoimmune or inflammatory disorders.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 10, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Louis M. Staudt, Yibin Yang, Federico Bernal, Amanda L. Whiting
  • Publication number: 20170081379
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 23, 2017
    Inventors: Federico BERNAL, Loren D. WALENSKY, Gregory L. VERDINE, Stanley J. KORSMEYER
  • Patent number: 9527896
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: December 27, 2016
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • Publication number: 20160031957
    Abstract: The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphboma (ABC DLBCL) and autoimmune or inflammatory disorders.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 4, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Louis M. Staudt, Yibin Yang, Federico Bernal
  • Publication number: 20150119551
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: September 11, 2014
    Publication date: April 30, 2015
    Applicants: President and Fellows of Harvard College, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Federico BERNAL, Loren D. WALENSKY, Gregory L. VERDINE
  • Patent number: 8889632
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: November 18, 2014
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
  • Publication number: 20140018302
    Abstract: Compositions and methods for increasing p53-dependent transcriptional activity in a cell.
    Type: Application
    Filed: November 14, 2011
    Publication date: January 16, 2014
    Applicants: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES INTELLECTUAL PROPERTY AND TECHNOLOGY, DANA FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Federico Bernal, Geoffrey Wahl, Mark Wade
  • Publication number: 20100168388
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Application
    Filed: January 31, 2008
    Publication date: July 1, 2010
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer, Susan Korsmeyer